SMARCB1 and neoplasm: Due to the rarity of the disease and the highly aggressive nature of the tumor, the current treatment options for SMARCB1-deficient RMC are not effective, with one study published in 2015 showing that the average overall survival of patients with SMARCB1-deficient RMC was only 6–8 months, with only one patient reaching 1 year [87].